By Owen Tucker-Smith
OS Therapies shares surged Wednesday after the biotech company reported positive data from a clinical trial for its cancer treatment OST-HER2.
Shares of the N.Y., clinical-stage biotechnology company were recently up 60% to $6.64 in premarket trading, which is above the stock's 52-week high of $6.48.
The trial tested whether OST-HER2 could successfully treat a rare form of bone cancer that spreads to the lungs. The company reported statistically significant results in the study's primary endpoint, which measured whether patients went 12 months without the recurrence of metastatic osteosarcoma.
The company also indicated promising results from patients at the 1-year and 2-year marks.
Robert Petit, the company's chief medical and scientific officer, said that the treatment would help a population for whom there are currently no approved therapies.
OS Therapies said that it plans to seek U.S. FDA accelerated approval for OST-HER2.
Write to Owen Tucker-Smith at owen.tucker-smith@wsj.com
(END) Dow Jones Newswires
January 15, 2025 09:33 ET (14:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。